Sanofi is set to release its quarterly earnings on October 24, 2025, with an expected EPS of $1.60 and revenue of approximately $12.4 billion.The company's recent success with efdoralprin alfa in the ElevAATe phase II study highlights its commitment to innovation and potential market growth.Financial metrics such as a P/E ratio of 11.66, enterprise value to operating cash flow ratio of 54.30, and a current ratio of 1.27 indicate Sanofi's stable financial position and market valuation.Sanofi (NASDAQ:SNY) is ...

Key Takeaways Sanofi's ElevAATe study showed that efdoralprin alfa met all primary and key secondary endpoints.Efdoralprin alfa achieved higher functional AAT levels versus weekly plasma-derived therapy.The therapy's Q3W and Q4W dosing regimen may enhance convenience for AATD patients.Sanofi (SNY) announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the treatment of alpha-1 antitrypsin deficiency (AATD) emphysema, met all primary and key secondary endpoin ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...